Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Mar. 31, 2017 | May 11, 2017 | |
Document And Entity Information | ||
Entity Registrant Name | PALATIN TECHNOLOGIES INC | |
Entity Central Index Key | 911,216 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2017 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --06-30 | |
Is Entity a Well-known Seasoned Issuer? | No | |
Is Entity a Voluntary Filer? | No | |
Is Entity's Reporting Status Current? | Yes | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 152,801,806 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2,017 |
Consolidated Balance Sheets (Un
Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2017 | Jun. 30, 2016 |
Current assets: | ||
Cash and cash equivalents | $ 54,505,215 | $ 8,002,668 |
Available-for-sale investments | 924,790 | 1,380,556 |
Accounts receivable | 4,657,577 | 0 |
Prepaid expenses and other current assets | 1,064,112 | 1,313,841 |
Total current assets | 61,151,694 | 10,697,065 |
Property and equipment, net | 74,910 | 97,801 |
Other assets | 56,916 | 63,213 |
Total assets | 61,283,520 | 10,858,079 |
Current liabilities: | ||
Accounts payable | 1,243,144 | 713,890 |
Accrued expenses | 8,316,692 | 7,767,733 |
Notes payable, net of discount and debt issuance costs | 7,792,639 | 5,374,951 |
Capital lease obligations | 21,331 | 27,424 |
Deferred revenue | 53,833,828 | 0 |
Total current liabilities | 71,207,634 | 13,883,998 |
Notes payable, net of discount and debt issuance costs | 8,250,004 | 14,106,594 |
Capital lease obligations | 0 | 14,324 |
Other non-current liabilities | 684,831 | 439,130 |
Total liabilities | 80,142,469 | 28,444,046 |
Stockholders' (deficiency) equity: | ||
Preferred stock of $0.01 par value – authorized 10,000,000 shares: Series A Convertible: issued and outstanding 4,030 shares as of March 31, 2017 and June 30, 2016 | 40 | 40 |
Common stock of $0.01 par value – authorized 300,000,000 shares: issued and outstanding 144,893,690 shares as of March 31, 2017 and 68,568,055 shares as of June 30, 2016, respectively | 1,448,937 | 685,680 |
Additional paid-in capital | 349,752,596 | 325,142,509 |
Accumulated other comprehensive loss | (1,419) | (1,944) |
Accumulated deficit | (370,059,103) | (343,412,252) |
Total stockholders’ deficiency | (18,858,949) | (17,585,967) |
Total liabilities and stockholders’ deficiency | $ 61,283,520 | $ 10,858,079 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2017 | Jun. 30, 2016 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, Series A Convertible, shares issued | 4,030 | 4,030 |
Preferred stock, Series A Convertible, shares outstanding | 4,030 | 4,030 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 300,000,000 | 300,000,000 |
Common stock, shares issued | 144,893,690 | 68,568,055 |
Common stock, shares outstanding | 144,893,690 | 68,568,055 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2017 | Mar. 31, 2016 | Mar. 31, 2017 | Mar. 31, 2016 | |
REVENUES: | ||||
Contract revenue | $ 10,823,748 | $ 0 | $ 10,823,748 | $ 0 |
OPERATING EXPENSES: | ||||
Research and development | 9,062,316 | 10,676,342 | 28,422,975 | 32,546,363 |
General and administrative | 4,773,696 | 1,409,406 | 7,289,342 | 3,965,460 |
Total operating expenses | 13,836,012 | 12,085,748 | 35,712,317 | 36,511,823 |
Loss from operations | (3,012,264) | (12,085,748) | (24,888,569) | (36,511,823) |
OTHER INCOME (EXPENSE): | ||||
Interest income | 6,304 | 15,062 | 18,940 | 39,036 |
Interest expense | (558,702) | (625,832) | (1,777,222) | (1,883,334) |
Total other income (expense), net | (552,398) | (610,770) | (1,758,282) | (1,844,298) |
NET LOSS | $ (3,564,662) | $ (12,696,518) | $ (26,646,851) | $ (38,356,121) |
Basic and diluted net loss per common share | $ (0.02) | $ (0.08) | $ (0.15) | $ (0.25) |
Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share | 196,580,519 | 156,368,617 | 179,841,133 | 156,301,259 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2017 | Mar. 31, 2016 | Mar. 31, 2017 | Mar. 31, 2016 | |
Consolidated Statements Of Comprehensive Loss | ||||
Net loss | $ (3,564,662) | $ (12,696,518) | $ (26,646,851) | $ (38,356,121) |
Other comprehensive income (loss): | ||||
Unrealized gain (loss) on available-for-sale investments | 587 | 6,819 | 525 | (5,270) |
Total comprehensive loss | $ (3,564,075) | $ (12,689,699) | $ (26,646,326) | $ (38,358,691) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (26,646,851) | $ (38,356,121) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 22,891 | 33,221 |
Non-cash interest expense | 234,056 | 244,476 |
Stock-based compensation | 1,404,721 | 1,318,298 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (4,657,577) | 0 |
Prepaid expenses and other assets | 256,026 | 447,824 |
Accounts payable | 529,254 | 676,798 |
Accrued expenses | 546,474 | 1,710,417 |
Deferred revenue | 53,833,828 | 0 |
Other non-current liabilities | 245,701 | 260,870 |
Net cash used in operating activities | 25,768,523 | (33,664,217) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Proceeds from matured investments | 450,000 | 0 |
Purchases of investments | 0 | (1,387,022) |
Purchases of property and equipment | 0 | (17,695) |
Net cash used in investing activities | 450,000 | (1,404,717) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Payments on capital lease obligations | (20,418) | (19,262) |
Payment of withholding taxes related to restricted stock units | (222) | (131,959) |
Payments on notes payable obligations | (3,666,666) | 0 |
Proceeds from exercise of warrants | 114,358 | 0 |
Proceeds from the sale of warrants, net of costs | 23,856,972 | 19,834,278 |
Proceeds from the issuance of notes payable and warrants | 0 | 10,000,000 |
Payment of debt issuance costs | 0 | (146,115) |
Net cash provided by financing activities | 20,284,024 | 29,536,942 |
NET INCREASE IN CASH AND CASH EQUIVALENTS | 46,502,547 | (5,531,992) |
CASH AND CASH EQUIVALENTS, beginning of period | 8,002,668 | 27,299,268 |
CASH AND CASH EQUIVALENTS, end of period | 54,505,215 | 21,767,276 |
SUPPLEMENTAL CASH FLOW INFORMATION: | ||
Cash paid for interest | 1,299,731 | 1,377,987 |
Issuance of warrants in connection with debt financing | 0 | 305,196 |
Unrealized loss on available-for-sale investments | $ 0 | $ 2,570 |
ORGANIZATION
ORGANIZATION | 9 Months Ended |
Mar. 31, 2017 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
ORGANIZATION | Nature of Business The Company’s primary product in development is bremelanotide for the treatment of HSDD, which is a type of FSD. The Company also has drug candidates and development programs for cardiovascular diseases, inflammatory diseases, obesity and dermatologic diseases. Key elements of the Company’s business strategy include using its technology and expertise to develop and commercialize therapeutic products; entering into alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale and distribution of product candidates that it is developing; partially funding its product development programs with the cash flow generated from current and future agreements with third parties; and completing development and seeking regulatory approval of its other product candidates. Business Risk and Liquidity – On January 8, 2017, the Company entered into an exclusive license agreement (License Agreement) with AMAG for bremelanotide for North America (Note 6). The License Agreement became effective on February 2, 2017 (Effective Date), and the Company received an upfront payment of $60,000,000 pursuant to the License Agreement on the Effective Date. As of March 31, 2017, the Company’s cash, cash equivalents and investments were $55,430,005 and current liabilities were $17,373,806, net of deferred revenue of $53,833,828. The Company intends to utilize existing capital resources for general corporate purposes and working capital, including required ancillary studies with bremelanotide for HSDD preparatory to filing a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA), and preclinical and clinical development of our other product candidates and programs, including natriuretic peptide receptor and melanocortin receptor programs. Management believes that with the proceeds from the License Agreement with AMAG and the proceeds from the financing transactions on August 4, 2016 and December 6, 2016, the Company has sufficient resources to fund its planned operations through the 2018 calendar year. The Company will need additional funding to complete required clinical trials for its other product candidates and, assuming those clinical trials are successful, as to which there can be no assurance, to complete submission of required applications to the FDA. If the Company is unable to obtain approval or otherwise advance in the FDA approval process, the Company’s ability to sustain its operations would be materially adversely affected. The Company may seek the additional capital necessary to fund its operations through public or private equity offerings, collaboration agreements, debt financings or licensing arrangements. Additional capital that is required by the Company may not be available on reasonable terms, or at all. Concentrations – |
BASIS OF PRESENTATION
BASIS OF PRESENTATION | 9 Months Ended |
Mar. 31, 2017 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
BASIS OF PRESENTATION | The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three and nine months ended March 31, 2017 may not necessarily be indicative of the results of operations expected for the full year. The accompanying consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2016, filed with the SEC, which includes consolidated financial statements as of June 30, 2016 and 2015 and for each of the fiscal years in the three-year period ended June 30, 2016. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
Mar. 31, 2017 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | Principles of Consolidation Use of Estimates Cash and Cash Equivalents Investments The fair value of substantially all securities is determined by quoted market prices. The estimated fair value of securities for which there are no quoted market prices is based on similar types of securities that are traded in the market. Fair Value of Financial Instruments Credit Risk Property and Equipment Impairment of Long-Lived Assets Revenue Recognition Revenue Recognition for Arrangements with Multiple Elements ● the delivered item has value to the customer on a stand-alone basis; and ● if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in control of the vendor. Under FASB ASC Topic 605-25, if both of the criteria above are not met, then separate accounting for the individual deliverables is not appropriate. The Company has determined that it is appropriate to recognize such revenue using the input-based proportional method during the period of the Palatin Development Obligation as defined in the AMAG arrangement. Refer to Note 6 for additional information. Revenue resulting from the achievement of development milestones is recorded in accordance with the accounting guidance for the milestone method of revenue recognition. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the Company’s consolidated balance sheet. Amounts expected to be recognized as revenue in the next 12 months following the balance sheet date are classified as current liabilities. Research and Development Costs Accrued Expenses – Stock-Based Compensation – Income Taxes Net Loss per Common Share The Series B 2012 warrants issued on July 3, 2012 to purchase up to 35,488,380 shares of common stock are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share for all periods presented in the consolidated statements of operations. The Series C 2014 warrants to purchase up to 24,949,325 shares of common stock were exercisable starting at December 23, 2014 and, therefore are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share starting on December 23, 2014. The Series E 2015 warrants to purchase up to 21,917,808 shares of common stock were exercisable starting at July 2, 2015 and, therefore are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share starting on July 2, 2015. The Series I 2016 warrants to purchase up to 2,218,045 shares of common stock were exercisable starting at August 4, 2016 and, therefore are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share starting on August 4, 2016 (Note 12). As of March 31, 2017 and 2016, common stock issuable upon conversion of Series A Convertible Preferred Stock, the exercise of outstanding options and warrants (excluding the Series A 2012, Series B 2012, Series C 2014, Series E 2015 and Series I 2016 warrants issued in connection with the July 3, 2012, December 23, 2014, and July 2, 2015 private placement offerings and the August 4, 2016 underwritten offering), and the vesting of restricted stock units amounted to an aggregate of 36,222,569, and 32,453,811 shares, respectively. These share amounts have been excluded from the calculation of net loss per share as the impact would be antidilutive. |
NEW AND RECENTLY ADOPTED ACCOUN
NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS | 9 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS | In June 2016, the FASB issued ASU No. 2016--13, Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments, In March 2016, the FASB issued ASU No. 2016--09, Compensation – Improvement to Employee Share-Based Payment Accounting In February 2016, the FASB issued ASU No. 2016--02, Leases, Related to the Recognition of Lease Assets and Lease Liabilities In January 2016, the FASB issued ASU No. 2016--01, Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities In November 2015, the FASB issued ASU No. 2015--17, Income Taxes: Balance Sheet Classification of Deferred Taxes, In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern: Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Identifying Performance Obligations and Licensing |
AGREEMENT WITH GEDEON RICHTER
AGREEMENT WITH GEDEON RICHTER | 9 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
AGREEMENT WITH GEDEON RICHTER | In August 2014, the Company entered into a license, co-development and commercialization agreement with Gedeon Richter on bremelanotide for FSD in Europe and selected countries. On September 16, 2015, the Company and Gedeon Richter mutually and amicably agreed to terminate the license, co-development and commercialization agreement. In connection with the termination of the license agreement, all rights and licenses to co-develop and commercialize bremelanotide for FSD indications granted by the Company under the license agreement to Gedeon Richter terminated and reverted to the Company, and neither party is expected to have any future material obligations under the license agreement. Neither the Company nor Gedeon Richter incurred any early termination penalties or other payment or reimbursement obligations as a result of the termination of the license agreement. The Company viewed the delivery of the license for bremelanotide as a revenue generating activity that is part of its ongoing and central operations. The other elements of the agreement with Gedeon Richter were considered non-revenue activities associated with the collaborative arrangement. The Company believes the license had standalone value from the other elements of the collaborative arrangement because it conveyed all of the rights necessary to develop and commercialize bremelanotide in the licensed territory. For the three and six months ended December 31, 2016, and 2015, the Company had no revenues reported. |
AGREEMENT WITH AMAG
AGREEMENT WITH AMAG | 9 Months Ended |
Mar. 31, 2017 | |
Agreement With Amag | |
AGREEMENT WITH AMAG | On January 8, 2017, the Company entered into the License Agreement with AMAG. Under the terms of the License Agreement, the Company granted to AMAG (i) an exclusive license in all countries of North America (the Territory), with the right to grant sub-licenses, to research, develop and commercialize products containing bremelanotide (each a Product, and collectively, Products), (ii) a non-exclusive license in the Territory, with the right to grant sub-licenses, to manufacture Products, and (iii) a non-exclusive license in all countries outside the Territory, with the right to grant sub-licenses, to research, develop and manufacture (but not commercialize) the Products. Following the satisfaction of certain conditions to closing, the License Agreement became effective on February 2, 2017. On the Effective Date AMAG paid the Company $60,000,000 as a one-time initial payment. Pursuant to the terms of and subject to the conditions in the License Agreement, AMAG is required to pay the Company up to an aggregate amount of $25,000,000 to reimburse the Company for reasonable, documented, direct out-of-pocket expenses incurred by the Company following the Effective Date, in connection with the development and regulatory activities necessary to file an NDA for bremelanotide for HSDD in the United States related to Palatin’s Development Obligation. The Company has determined there is no stand-alone value for the license, and that the license and the reimbursable direct out-of-pocket expenses represent a combined unit of accounting which totals $85,000,000. The Company is recognizing revenue of the combined unit of accounting over the arrangement using the input-based proportional method as the Company completes the Palatin Development Obligation. For the three and nine months ended March 31, 2017, respectively, the Company recognized $10,823,748 as contract revenue related to the license, including $4,657,577 of expense reimbursement incurred, invoiced and included in accounts receivable as of March 31, 2017. As of March 31, 2017, there is $53,833,828 of current deferred revenue, related to the upfront payment on the consolidated balance sheet. In addition, pursuant to the terms of and subject to the conditions in the License Agreement, the Company will be eligible to receive from AMAG: (i) up to $80,000,000 in specified regulatory payments upon achievement of certain regulatory milestones, and (ii) up to $300,000,000 in sales milestone payments based on achievement of annual net sales amounts for all Products in the Territory. AMAG is also obligated to pay the Company tiered royalties on annual net sales of Products, on a product-by-product basis, in the Territory ranging from the high single-digits to the low double-digits. The royalties will expire on a product-by-product and country-by-country basis until the latest to occur of (i) the earliest date on which there are no valid claims of the Company’s patent rights covering such Product in such country, (ii) the expiration of the regulatory exclusivity period for such Product in such country and (iii) ten years following the first commercial sale of such Product in such country. Such royalties are subject to reductions in the event that: (a) AMAG must license additional third party intellectual property in order to develop, manufacture or commercialize a Product, or (b) generic competition occurs with respect to a Product in a given country, subject to an aggregate cap on such deductions of royalties otherwise payable to the Company. After the expiration of the applicable royalties for any Product in a given country, the license for such Product in such country will become a fully paid-up, royalty-free, perpetual and irrevocable license. The Company engaged Greenhill & Co. LLC (Greenhill) as the Company’s sole financial advisor in connection with a potential transaction with respect to bremelanotide. Under the engagement agreement with Greenhill, the Company was obligated to pay Greenhill a fee equal to 2% of all proceeds and consideration paid to the Company by AMAG in connection with the License Agreement, subject to a minimum fee of $2,500,000. The minimum fee of $2,500,000, less credit of $50,000 for an advisory fee previously paid by the Company, was paid to Greenhill upon the closing of the licensing transaction. This amount will be credited toward amounts that become due to Greenhill in the future, provided that the aggregate fee payable to Greenhill will not be less than 2% of all proceeds and consideration paid to the Company by AMAG in connection with the License Agreement. The Company will pay Greenhill an aggregate total of 2% of all proceeds and consideration paid to the Company by AMAG in connection with the License Agreement after crediting the $2,500,000 that was paid to Greenhill upon entering into the License Agreement with AMAG. The Company also reimbursed Greenhill $7,263 for certain expenses incurred in connection with its advisory services. Pursuant to the License Agreement, the Company has assigned to AMAG the Company’s manufacturing and supply agreements with Catalent Belgium S.A. to perform fill, finish and packaging of bremelanotide. |
PREPAID EXPENSES AND OTHER CURR
PREPAID EXPENSES AND OTHER CURRENT ASSETS | 9 Months Ended |
Mar. 31, 2017 | |
Prepaid Expenses And Other Current Assets | |
PREPAID EXPENSES AND OTHER CURRENT ASSETS | Prepaid expenses and other current assets consist of the following: March 31, 2017 June 30, 2016 Clinical study costs $ 640,348 $ 1,146,975 Insurance premiums 181,996 23,010 Other 241,768 143,856 $ 1,064,112 $ 1,313,841 |
INVESTMENTS
INVESTMENTS | 9 Months Ended |
Mar. 31, 2017 | |
Investments | |
INVESTMENTS | The following summarizes the carrying value of our available-for-sale investments, which consist of corporate debt securities: March 31, 2017 June 30, 2016 Cost $ 1,387,022 $ 1,387,022 Matured (450,000 ) $ - Amortization of premium (10,813 ) (4,522 ) Gross unrealized loss (1,419 ) (1,944 ) Fair value $ 924,790 $ 1,380,556 |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 9 Months Ended |
Mar. 31, 2017 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENTS | The fair value of cash equivalents is classified using a hierarchy prioritized based on inputs. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management’s own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The following table provides the assets carried at fair value: Carrying Value Quoted prices in active markets (Level 1) Other quoted/observable inputs (Level 2) Significant unobservable inputs (Level 3) March 31, 2017: Money market account $ 54,326,743 $ 54,326,743 $ - $ - TOTAL 54,326,743 54,326,743 - - June 30, 2016: Money market account 7,782,243 7,782,243 - - TOTAL $ 7,782,243 $ 7,782,243 $ - $ - |
ACCRUED EXPENSES
ACCRUED EXPENSES | 9 Months Ended |
Mar. 31, 2017 | |
Accrued Expenses | |
ACCRUED EXPENSES | Accrued expenses consist of the following: March 31, 2017 June 30, 2016 Bremelanotide program costs $ 7,739,920 $ 6,983,581 Other research related expenses 237,841 69,609 Professional services 78,751 231,482 Other 260,180 483,061 $ 8,316,692 $ 7,767,733 |
NOTES PAYABLE
NOTES PAYABLE | 9 Months Ended |
Mar. 31, 2017 | |
Debt Disclosure [Abstract] | |
NOTES PAYABLE | Notes payable consist of the following: March 31, 2017 June 30, 2016 Notes payable under venture loan $ 16,333,334 $ 20,000,000 Unamortized related debt discount (183,478 ) (324,800 ) Unamortized debt issuance costs (107,213 ) (193,655 ) Notes payable 16,042,643 19,481,545 Less: current portion 7,792,639 5,374,951 Long-term portion $ 8,250,004 $ 14,106,594 On December 23, 2014, the Company closed on a $10,000,000 venture loan which was led by Horizon. The debt facility is a four year senior secured term loan that bears interest at a floating coupon rate of one-month LIBOR (floor of 0.50%) plus 8.50%, and provides for interest-only payments for the first eighteen months followed by monthly payments of principal payments of $333,333 plus accrued interest through January 1, 2019. The lenders also received five-year immediately exercisable Series D 2014 warrants to purchase 666,666 shares of common stock exercisable at an exercise price of $0.75 per share. The Company recorded a debt discount of $267,820 equal to the fair value of these warrants at issuance, which is being amortized to interest expense over the term of the related debt. This debt discount is offset against the note payable balance and included in additional paid-in capital on the Company’s balance sheet at March 31, 2017, and June 30, 2016. In addition, a final incremental payment of $500,000 is due on January 1, 2019, or upon early repayment of the loan. This final incremental payment is being accreted to interest expense over the term of the related debt. The Company incurred $209,000 of costs in connection with the loan. These costs were capitalized as deferred financing costs and are offset against the note payable balance. These debt issuance costs are being amortized to interest expense over the term of the related debt. In addition, if the Company repays all or a portion of the loan prior to the applicable maturity date, it will pay the lenders a prepayment penalty fee, based on a percentage of the then outstanding principal balance, equal to 3% if the prepayment occurs on or before 18 months after the funding date thereof or 1% if the prepayment occurs more than 18 months after, but on or before 30 months after, the funding date. On July 2, 2015, the Company closed on a $10,000,000 venture loan led by Horizon Technology Finance Corporation (Horizon). The debt facility is a four-year senior secured term loan that bears interest at a floating coupon rate of one-month LIBOR (floor of 0.50%) plus 8.50% and provides for interest-only payments for the first eighteen months followed by monthly payments of principal payments of $333,333 plus accrued interest through August 1, 2019. The lenders also received five-year immediately exercisable Series G warrants to purchase 549,450 shares of the Company’s common stock exercisable at an exercise price of $0.91 per share. The Company has recorded a debt discount of $305,196 equal to the fair value of these warrants at issuance, which is being amortized to interest expense over the term of the related debt. This debt discount will offset against the note payable balance and is included in additional paid-in capital on the Company’s balance sheet at March 31, 2017 and June 30, 2016. In addition, a final incremental payment of $500,000 is due on August 1, 2019, or upon early repayment of the loan. This final incremental payment is being accreted to interest expense over the term of the related debt. The Company incurred approximately $146,000 of costs in connection with the loan agreement. These costs were capitalized as deferred financing costs and are offset against the note payable balance. These debt issuance costs are being amortized to interest expense over the term of the related debt. In addition, if the Company repays all or a portion of the loan prior to the applicable maturity date, it will pay the lenders a prepayment penalty fee, based on a percentage of the then outstanding principal balance, equal to 3% if the prepayment occurs on or before 18 months after the funding date thereof or 1% if the prepayment occurs more than 18 months after, but on or before 30 months after, the funding date. The Company’s obligations under the 2015 amended and restated loan agreement, which includes both the 2014 venture loan and the 2015 venture loan, are secured by a first priority security interest in substantially all of its assets other than its intellectual property. The Company also has agreed to specified limitations on pledging or otherwise encumbering its intellectual property assets. The 2015 amended and restated loan agreement include customary affirmative and restrictive covenants, but does not include any covenants to attain or maintain specified financial metrics. The loan agreement includes customary events of default, including payment defaults, breaches of covenants, change of control and a material adverse change default. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the loan agreement. As of March 31, 2017, the Company was in compliance with all of its loan covenants. |
STOCKHOLDERS' (DEFICIENCY) EQUI
STOCKHOLDERS' (DEFICIENCY) EQUITY | 9 Months Ended |
Mar. 31, 2017 | |
Equity [Abstract] | |
STOCKHOLDERS' (DEFICIENCY) EQUITY | Financing Transactions – On August 4, 2016, the Company closed on an underwritten offering of units, with each unit consisting of a share of common stock and a Series H warrant to purchase 0.75 of a share of common stock. Investors whose purchase of units in the offering would result in them beneficially owning more than 9.99% of the Company’s outstanding common stock following the completion of the offering had the opportunity to acquire units with Series I prefunded warrants substituted for any common stock they would have otherwise acquired. Gross proceeds were $9,225,000, with net proceeds to the Company, after deducting offering expenses, of $8,470,897. The Company issued 11,481,481 shares of common stock and ten-year prefunded Series I warrants to purchase 2,218,045 shares of common stock at an exercise price of $0.01, together with Series H warrants to purchase 10,274,646 shares of common stock at an exercise price of $0.70 per share. The Series I warrants are exercisable at an initial exercise price of $0.01 per share, exercisable immediately upon issuance and expire on the tenth anniversary of the date of issuance. The Series I warrants are subject to limitation on exercise if the holder and its affiliates would beneficially own more than 9.99% of the total number of the Company’s shares of common stock following such exercise. The Series H warrants are exercisable at an initial exercise price of $0.70 per share, are exercisable commencing six months following the date of issuance and expire on the fifth anniversary of the date of issuance. The Series H warrants are subject to the same beneficial ownership limitation as the Series I warrants. On July 2, 2015, the Company closed on a private placement of Series E warrants to purchase 21,917,808 shares of Palatin common stock and Series F warrants to purchase 2,191,781 shares of the Company’s common stock. Certain funds managed by QVT Financial LP (QVT) invested $5,000,000 and another accredited investment fund invested $15,000,000. The funds paid $0.90 for each Series E warrant and $0.125 for each Series F warrant, resulting in gross proceeds to the Company of $20,000,000, with net proceeds, after deducting offering expenses, of $19,834,278. The Series E warrants, which may be exercised on a cashless basis, are exercisable immediately upon issuance at an initial exercise price of $0.01 per share and expire on the tenth anniversary of the date of issuance. The Series E warrants are subject to limitation on exercise if QVT and its affiliates would beneficially own more than 9.99% (4.99% for the other accredited investment fund holder) of the total number of the Company’s shares of common stock following such exercise. The Series F warrants are exercisable at an initial exercise price of $0.91 per share, exercisable immediately upon issuance and expire on the fifth anniversary of the date of issuance. The Series F warrants are subject to the same beneficial ownership limitation as the Series E warrants. The purchase agreement for the private placement provides that the purchasers have certain rights until the earlier of approval of bremelanotide for FSD by the FDA and July 3, 2018, including rights of first refusal and participation in any subsequent equity or debt financing. The purchase agreement also contains certain restrictive covenants so long as the funds continue to hold specified amounts of warrants or beneficially own specified amounts of the outstanding shares of common stock. During the nine months ended March 31, 2017, and 2016 the Company issued 27,989,685 shares and 10,890,889 shares, respectively, of common stock pursuant to the cashless exercise provisions of warrants at an exercise price of $0.01 per share, and during the nine months ended March 31, 2017, the Company issued 11,435,811 shares of common stock pursuant to the exercise of warrants at an exercise price of $0.01 per share. As of March 31, 2017, there were 50,610,953 warrants outstanding at an exercise price of $0.01 per share. Stock Options In June 2016, the Company granted 262,500 options to its non-employee directors under the Company’s 2011 Stock Incentive Plan. The Company is amortizing the fair value of these options of $81,435 over the vesting period. The Company recognized $20,359 and $61,077, respectively, of stock-based compensation expense related to these options during the three and nine months ended March 31, 2017. In June 2015, the Company granted 570,000 options to its executive officers, 185,800 options to its employees and 160,000 options to its non-employee directors under the Company’s 2011 Stock Incentive Plan. The Company is amortizing the fair value of these options of $446,748, $145,439 and $111,876, respectively, over the vesting period. The Company recognized $37,847, and $105,332, respectively, of stock-based compensation expense related to these options during the three and nine months ended March 31, 2017 and $62,443 and $187,328, respectively, during the three and nine months ended March 31, 2016. Unless otherwise stated, stock options granted to the Company’s executive officers and employees vest over a 48-month period, while stock options granted to its non-employee directors vest over a 12-month period. Restricted Stock Units In June 2016, the Company granted 262,500 restricted stock units to its non-employee directors under the Company’s 2011 Stock Incentive Plan. The Company is amortizing the fair value of these restricted stock units of $131,250 over the vesting period. The Company recognized $32,812 and $98,437, respectively, of stock-based compensation expense related to these restricted stock units during the three and nine months ended March 31, 2017. In December 2015, the Company granted 625,000 performance-based restricted stock units to its executive officers and 200,000 performance-based restricted stock units to its employees under the Company’s 2011 Stock Incentive Plan, which vest during the performance period, ending December 31, 2017, if and upon the earlier of: i) achievement of a closing price for the Company’s common stock equal to or greater than $1.20 per share for 20 consecutive trading days, which is considered a market condition, or ii) entering into a collaboration agreement (U.S. or global) of bremelanotide for FSD, which is considered a performance condition. This performance condition was deemed met as of February 2, 2017, the Effective Date of the License Agreement on bremelanotide with AMAG. Prior to meeting the performance condition, the Company determined that it was not probable of achievement on the date of grant since meeting the condition was outside the control of the Company. The fair value of these awards, as calculated under a multifactor Monte Carlo simulation, was $338,250 and was recognized over the derived service period which was through December 2016. Upon the achievement of the performance condition, which occurred in the three month period ended March 31, 2017 the grant date fair value was utilized and an incremental $222,075 was recognized as stock-based compensation expense during the three months ended March 31, 2017. The Company recognized $364,364 of stock-based compensation expense related to these restricted stock units during the nine months ended March 31, 2017. The Company recognized $86,879 and $109,082, respectively, of stock-based compensation expense related to these restricted stock units during the three and nine months ended March 31, 2016. Also, in December 2015, the Company granted 625,000 restricted stock units to its executive officers, 340,000 restricted stock units to its non-employee directors and 200,000 restricted stock units to its employees under the Company’s 2011 Stock Incentive Plan. For executive officers and employees, the restricted stock units vest 25% on the date of grant and 25% on the first, second and third anniversary dates from the date of grant. For non-employee directors, the restricted stock units vest 50% on the first and second anniversary dates from the date of grant. The fair value of these restricted stock units is $425,000, $231,200 and $136,000, respectively. The Company recognized $41,079 and $228,331, respectively, of stock-based compensation expense related to these restricted stock units during the three and nine months ended March 31, 2017. The Company recognized $107,631 and $275,387, respectively, of stock-based compensation expense related to these restricted stock units during the three and nine months ended March 31, 2016. In June 2015, the Company granted 400,000 restricted stock units to its executive officers, 185,800 restricted stock units to its employees and 160,000 restricted stock units to its non-employee directors under the Company’s 2011 Stock Incentive Plan. The Company is amortizing the fair value of these restricted stock units of $432,000, $200,664, and $172,800, respectively, over the vesting period. The Company recognized $35,336 and $116,195, respectively, of stock-based compensation expense related to these restricted stock units during the three and nine months ended March 31, 2017. The Company recognized $150,328 and $450,984, respectively, of stock-based compensation expense related to these restricted stock units during the three and nine months ended March 31, 2016. Unless otherwise stated, restricted stock units granted to the Company’s executive officers, employees and non-employee directors vest over 24 months, 48 months and 12 months, respectively. Stock-based compensation cost for the three and nine months ended March 31, 2017 for stock options and equity-based instruments issued other than the stock options and restricted stock units described above was $52,354 and $178,983, respectively, and $110,269 and $295,517, respectively, for the three and nine months ended March 31, 2016. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Mar. 31, 2017 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | Outstanding Common Stock – |
ORGANIZATION (Policies)
ORGANIZATION (Policies) | 9 Months Ended |
Mar. 31, 2017 | |
Organization Policies | |
Nature of Business | Palatin Technologies, Inc. (Palatin or the Company) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, cachexia (wasting syndrome) and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of acute asthma, heart failure, hypertension and other cardiovascular diseases. The Company’s primary product in development is bremelanotide for the treatment of HSDD, which is a type of FSD. The Company also has drug candidates and development programs for cardiovascular diseases, inflammatory diseases, obesity and dermatologic diseases. Key elements of the Company’s business strategy include using its technology and expertise to develop and commercialize therapeutic products; entering into alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale and distribution of product candidates that it is developing; partially funding its product development programs with the cash flow generated from current and future agreements with third parties; and completing development and seeking regulatory approval of its other product candidates. |
Business Risk and Liquidity | Since inception, the Company has incurred negative cash flows from operations, and has expended, and expects to continue to expend, substantial funds to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit as of March 31, 2017 of $370,059,103 and incurred a net loss for the three and nine months ended March 31, 2017 of $3,564,662 and $26,646,851, respectively. The Company anticipates incurring additional losses in the future as a result of spending on its development programs and will require substantial additional financing to continue to fund its planned developmental activities. To achieve profitability, if ever, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals and successfully manufacture and market such technologies and proposed products. The time required to reach profitability is highly uncertain, and the Company may never be able to achieve profitability on a sustained basis, if at all. On January 8, 2017, the Company entered into an exclusive license agreement (License Agreement) with AMAG for bremelanotide for North America (Note 6). The License Agreement became effective on February 2, 2017 (Effective Date), and the Company received an upfront payment of $60,000,000 pursuant to the License Agreement on the Effective Date. As of March 31, 2017, the Company’s cash, cash equivalents and investments were $55,430,005 and current liabilities were $17,373,806, net of deferred revenue of $53,833,828. The Company intends to utilize existing capital resources for general corporate purposes and working capital, including required ancillary studies with bremelanotide for HSDD preparatory to filing a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA), and preclinical and clinical development of our other product candidates and programs, including natriuretic peptide receptor and melanocortin receptor programs. Management believes that with the proceeds from the License Agreement with AMAG and the proceeds from the financing transactions on August 4, 2016 and December 6, 2016, the Company has sufficient resources to fund its planned operations through the 2018 calendar year. The Company will need additional funding to complete required clinical trials for its other product candidates and, assuming those clinical trials are successful, as to which there can be no assurance, to complete submission of required applications to the FDA. If the Company is unable to obtain approval or otherwise advance in the FDA approval process, the Company’s ability to sustain its operations would be materially adversely affected. The Company may seek the additional capital necessary to fund its operations through public or private equity offerings, collaboration agreements, debt financings or licensing arrangements. Additional capital that is required by the Company may not be available on reasonable terms, or at all. |
Concentrations | Concentrations in the Company’s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and available-for-sale investments. The Company’s cash and cash equivalents are primarily invested in one money market account sponsored by a large financial institution. For the three and nine months ended March 31, 2017, the Company reported $10,823,748 in contract revenue related to the License Agreement. The company did not generate any revenue for the three and nine months ended March 31, 2016. |
SUMMARY OF SIGNIFICANT ACCOUN21
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 9 Months Ended |
Mar. 31, 2017 | |
Summary Of Significant Accounting Policies Policies | |
Principles of Consolidation | The consolidated financial statements include the accounts of Palatin and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. |
Use of Estimates | The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Cash and Cash Equivalents | Cash and cash equivalents include cash on hand, cash in banks and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consist of $54,326,743 and $7,782,243 in a money market account at March 31, 2017 and June 30, 2016, respectively. |
Investments | The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Debt securities are classified as held-to-maturity when the Company has the intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Held-to-maturity securities are recorded as either short-term or long-term on the balance sheet, based on the contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of other comprehensive (loss) income. The fair value of substantially all securities is determined by quoted market prices. The estimated fair value of securities for which there are no quoted market prices is based on similar types of securities that are traded in the market. |
Fair Value of Financial Instruments | The Company’s financial instruments consist primarily of cash equivalents, accounts receivable, available-for-sale investments, accounts payable and notes payable. Management believes that the carrying values of cash equivalents, accounts receivable, available-for-sale investments and accounts payable are representative of their respective fair values based on the short-term nature of these instruments. Management believes that the carrying amount of its notes payable approximates fair value based on the terms of the notes. |
Credit Risk | – Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded insured balances by the Federal Depository Insurance Company. |
Property and Equipment | Property and equipment consists of office and laboratory equipment, office furniture and leasehold improvements and includes assets acquired under capital leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under capital leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized. |
Impairment of Long-Lived Assets | The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions. |
Revenue Recognition | The Company has generated revenue solely through license and collaboration agreements. The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, Revenue Recognition for Arrangements with Multiple Elements ● the delivered item has value to the customer on a stand-alone basis; and ● if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in control of the vendor. Under FASB ASC Topic 605-25, if both of the criteria above are not met, then separate accounting for the individual deliverables is not appropriate. The Company has determined that it is appropriate to recognize such revenue using the input-based proportional method during the period of the Palatin Development Obligation as defined in the AMAG arrangement. Refer to Note 6 for additional information. Revenue resulting from the achievement of development milestones is recorded in accordance with the accounting guidance for the milestone method of revenue recognition. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the Company’s consolidated balance sheet. Amounts expected to be recognized as revenue in the next 12 months following the balance sheet date are classified as current liabilities. |
Research and Development Costs | The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use. |
Accrued Expenses | Third parties perform a significant portion of our development activities. We review the activities performed under significant contracts each quarter and accrue expenses and the amount of any reimbursement to be received from our collaborators based upon the estimated amount of work completed. Estimating the value or stage of completion of certain services requires judgment based on available information. If we do not identify services performed for us but not billed by the service-provider, or if we underestimate or overestimate the value of services performed as of a given date, reported expenses, as well as revenue, will be understated or overstated. |
Stock-Based Compensation | The Company charges to expense the fair value of stock options and other equity awards granted. The Company determines the value of stock options utilizing the Black-Scholes option pricing model. Compensation costs for share-based awards with pro-rata vesting are determined using the quoted market price of the Company’s common stock on the date of grant and allocated to periods on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations. |
Income Taxes | The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded a valuation allowance against its deferred tax assets based on the history of losses incurred. |
Net Loss per Common Share | Basic and diluted earnings per common share (EPS) are calculated in accordance with the provisions of FASB ASC Topic 260, “Earnings per Share,” which includes guidance pertaining to the warrants, issued in connection with the July 3, 2012, December 23, 2014, and July 2, 2015 private placement offerings and the August 4, 2016 underwritten offering, that are exercisable for nominal consideration and, therefore, are to be considered in the computation of basic and diluted net loss per common share. The Series A 2012 warrants issued on July 3, 2012 to purchase up to 31,988,151 shares of common stock are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share for all periods presented in the consolidated statements of operations. The Series B 2012 warrants issued on July 3, 2012 to purchase up to 35,488,380 shares of common stock are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share for all periods presented in the consolidated statements of operations. The Series C 2014 warrants to purchase up to 24,949,325 shares of common stock were exercisable starting at December 23, 2014 and, therefore are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share starting on December 23, 2014. The Series E 2015 warrants to purchase up to 21,917,808 shares of common stock were exercisable starting at July 2, 2015 and, therefore are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share starting on July 2, 2015. The Series I 2016 warrants to purchase up to 2,218,045 shares of common stock were exercisable starting at August 4, 2016 and, therefore are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share starting on August 4, 2016 (Note 12). As of March 31, 2017 and 2016, common stock issuable upon conversion of Series A Convertible Preferred Stock, the exercise of outstanding options and warrants (excluding the Series A 2012, Series B 2012, Series C 2014, Series E 2015 and Series I 2016 warrants issued in connection with the July 3, 2012, December 23, 2014, and July 2, 2015 private placement offerings and the August 4, 2016 underwritten offering), and the vesting of restricted stock units amounted to an aggregate of 36,222,569, and 32,453,811 shares, respectively. These share amounts have been excluded from the calculation of net loss per share as the impact would be antidilutive. |
PREPAID EXPENSES AND OTHER CU22
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) | 9 Months Ended |
Mar. 31, 2017 | |
Prepaid Expenses And Other Current Assets Tables | |
Schedule of prepaid expenses and other current assets | March 31, 2017 June 30, 2016 Clinical study costs $ 640,348 $ 1,146,975 Insurance premiums 181,996 23,010 Other 241,768 143,856 $ 1,064,112 $ 1,313,841 |
INVESTMENTS (Tables)
INVESTMENTS (Tables) | 9 Months Ended |
Mar. 31, 2017 | |
Investments Tables | |
Carrying value of our available-for-sale investments | March 31, 2017 June 30, 2016 Cost $ 1,387,022 $ 1,387,022 Matured (450,000 ) $ - Amortization of premium (10,813 ) (4,522 ) Gross unrealized loss (1,419 ) (1,944 ) Fair value $ 924,790 $ 1,380,556 |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 9 Months Ended |
Mar. 31, 2017 | |
Fair value of restricted stock units granted, amortized over 24 month vesting period | |
Schedule of assets at fair value | Carrying Value Quoted prices in active markets (Level 1) Other quoted/observable inputs (Level 2) Significant unobservable inputs (Level 3) March 31, 2017: Money market account $ 54,326,743 $ 54,326,743 $ - $ - TOTAL 54,326,743 54,326,743 - - June 30, 2016: Money market account 7,782,243 7,782,243 - - TOTAL $ 7,782,243 $ 7,782,243 $ - $ - |
ACCRUED EXPENSES (Tables)
ACCRUED EXPENSES (Tables) | 9 Months Ended |
Mar. 31, 2017 | |
Accrued Expenses | |
Accrued Expenses | March 31, 2017 June 30, 2016 Bremelanotide program costs $ 7,739,920 $ 6,983,581 Other research related expenses 237,841 69,609 Professional services 78,751 231,482 Other 260,180 483,061 $ 8,316,692 $ 7,767,733 |
NOTES PAYABLE (Tables)
NOTES PAYABLE (Tables) | 9 Months Ended |
Mar. 31, 2017 | |
Debt Disclosure [Abstract] | |
Notes Payable | March 31, 2017 June 30, 2016 Notes payable under venture loan $ 16,333,334 $ 20,000,000 Unamortized related debt discount (183,478 ) (324,800 ) Unamortized debt issuance costs (107,213 ) (193,655 ) Notes payable 16,042,643 19,481,545 Less: current portion 7,792,639 5,374,951 Long-term portion $ 8,250,004 $ 14,106,594 |
ORGANIZATION (Details Narrative
ORGANIZATION (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Mar. 31, 2017 | Mar. 31, 2016 | Mar. 31, 2017 | Mar. 31, 2016 | Jun. 30, 2016 | |
Accumulated deficit | $ 370,059,103 | $ 370,059,103 | $ 343,412,252 | ||
Net loss | 3,564,662 | $ 12,696,518 | 26,646,851 | $ 38,356,121 | |
Cash, cash equivalents and investments | $ 55,430,005 | $ 55,430,005 |
SUMMARY OF SIGNIFICANT ACCOUN28
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | Mar. 31, 2017 | Jun. 30, 2016 |
Range 6 | ||
Cash equivalents | $ 54,326,743 | $ 7,782,243 |
PREPAID EXPENSES AND OTHER CU29
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) | Mar. 31, 2017 | Jun. 30, 2016 |
Prepaid Expenses And Other Current Assets Details | ||
Clinical study costs | $ 640,348 | $ 1,146,975 |
Deferred financing costs | 181,996 | 23,010 |
Other | 241,768 | 143,856 |
Total prepaid expenses and other current assets | $ 1,064,112 | $ 1,313,841 |
INVESTMENTS (Details)
INVESTMENTS (Details) - USD ($) | Mar. 31, 2017 | Jun. 30, 2016 |
Investments Details | ||
Cost | $ 1,387,022 | $ 1,387,022 |
Matured | (450,000) | 0 |
Amortization of premium | (10,813) | (4,522) |
Gross unrealized loss | (1,419) | (1,944) |
Fair value | $ 924,790 | $ 1,380,556 |
FAIR VALUE MEASUREMENTS (Detail
FAIR VALUE MEASUREMENTS (Details) - USD ($) | Mar. 31, 2017 | Jun. 30, 2016 |
Money Market Account | $ 54,326,743 | $ 7,782,243 |
Total | 54,326,743 | 7,782,243 |
Level 1 | ||
Money Market Account | 54,326,743 | 7,782,243 |
Total | 54,326,743 | 7,782,243 |
Level 2 | ||
Money Market Account | 0 | 0 |
Total | 0 | 0 |
Level 3 | ||
Money Market Account | 0 | 0 |
Total | $ 0 | $ 0 |
ACCRUED EXPENSES (Details)
ACCRUED EXPENSES (Details) - USD ($) | Mar. 31, 2017 | Jun. 30, 2016 |
Accrued Expenses | ||
Bremelanotide Program costs | $ 7,739,920 | $ 6,983,581 |
Other research related expenses | 237,841 | 69,609 |
Professional services | 78,751 | 231,482 |
Other | 260,180 | 483,061 |
Accrued expenses | $ 8,316,692 | $ 7,767,733 |
NOTES PAYABLE (Details)
NOTES PAYABLE (Details) - USD ($) | Mar. 31, 2017 | Jun. 30, 2016 |
Notes Payable Details | ||
Notes payable under venture loan | $ 16,333,334 | $ 20,000,000 |
Unamortized related debt discountUnamortized related debt discount | (183,478) | (324,800) |
Unamortized debt issuance costs | (107,213) | (193,655) |
Notes payable | 16,042,643 | 19,481,545 |
Less: current portion | 7,792,639 | 5,374,951 |
Long-term portion | $ 8,250,004 | $ 14,106,594 |
STOCKHOLDERS' (DEFICIENCY) EQ34
STOCKHOLDERS' (DEFICIENCY) EQUITY (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2017 | Mar. 31, 2016 | Mar. 31, 2017 | Mar. 31, 2016 | |
Stock based compensation | $ 52,354 | $ 110,269 | $ 178,983 | $ 295,517 |
2011 Stock Incentive Plan | Restricted Stock Units | Grant One | ||||
Stock based compensation | 76,822 | 177,554 | ||
2011 Stock Incentive Plan | Restricted Stock Units | Grant Two | ||||
Stock based compensation | 32,812 | 0 | 98,437 | 0 |
2011 Stock Incentive Plan | Restricted Stock Units | Grant Three | ||||
Stock based compensation | 222,075 | 86,879 | 364,364 | 109,082 |
2011 Stock Incentive Plan | Restricted Stock Units | Grant Four | ||||
Stock based compensation | 41,079 | 107,631 | 228,331 | 275,387 |
2011 Stock Incentive Plan | Restricted Stock Units | Grant Five | ||||
Stock based compensation | 35,336 | 150,328 | 116,195 | 450,984 |
2011 Stock Incentive Plan | Stock Options | Grant One | ||||
Stock based compensation | 16,426 | 38,210 | ||
2011 Stock Incentive Plan | Stock Options | Grant Two | ||||
Stock based compensation | 16,370 | 36,238 | ||
2011 Stock Incentive Plan | Stock Options | Grant Three | ||||
Stock based compensation | 20,359 | 61,077 | ||
2011 Stock Incentive Plan | Stock Options | Grant Four | ||||
Stock based compensation | $ 37,847 | $ 62,443 | $ 105,332 | $ 187,328 |